Advertisement
"GSK is honored to sponsor this award which is being presented to Dr.Daniel Hayes, a dedicated researcher who has been at the forefront ofindividualized breast cancer therapy," said Paolo Paoletti, MD, Senior VicePresident of the Oncology Medicine Development Center at GlaxoSmithKline. "Hiscontributions to the field of oncology have had an important impact on ourknowledge about monitoring and managing the disease, and his findings havetranslated into real-world benefits for patients."
Advertisement
Dr. Hayes, who is Clinical Director of the Breast Oncology Program at theUniversity of Michigan Comprehensive Cancer Center, is a widely recognizedexpert in breast cancer clinical research, particularly with new hormonal andchemotherapeutic treatments. He and his colleagues published the firstreports on the CA15-3 blood test, currently used worldwide to evaluate breastcancer patients. Dr. Hayes' more recent research focuses on pharmacogenomics,and understanding the key role genes play in chemotherapy treatment.
The new award and an accompanying fellowship were created in honor of oneof the giants of modern-day medical oncology, Dr. Gianni Bonadonna, of theInstituto Nazionale Tumori in Milan, Italy. Dr. Bonadonna was responsible forground-breaking research in adjuvant treatment of breast cancer and thedevelopment of the combination chemotherapy regimen that remains thegold-standard treatment for Hodgkin's disease today.
"Gianni Bonadonna's work revolutionized the management and treatment ofbreast cancer," said Gabriel Hortobagyi, MD, immediate past president of ASCO."Dr. Daniel Hayes is receiving a well-deserved recognition of his impressiveresearch achievements and, I believe that Dr. Hayes, like Bonadonna, willcontinue to be an outstanding role model for younger oncology researchers."
About the Gianni Bonadonna Breast Cancer Award and Fellowship
'The Gianni Bonadonna Breast Cancer Award and Lecture', a $10,000 award,will be presented annually to a researcher of merit in the field of breastcancer. The award is accompanied by a fellowship grant, presented to anearly-career breast cancer researcher who will work in the lab at therecipient's institution. 'The Gianni Bonadonna Breast Cancer ResearchFellowship' will consist of a one-year grant of $50,000 in support of thefellow's research. The fellow will be announced at a later date.
In 1973, Dr. Bonadonna designed and conducted the first randomized studyto test the activity of the CMF (cyclophosphamide, methotrexate andfluorouracil) combination chemotherapy as an adjuvant treatment innode-positive operable breast cancer. Adjuvant CMF proved to be effective insignificantly reducing the risk of disease recurrence and death over aprolonged period of time (30 years).
About GlaxoSmithKline
GlaxoSmithKline -- one of the world's leading research-basedpharmaceutical and healthcare companies -- is committed to improving thequality of human life by enabling people to do more, feel better, and livelonger. For company information, visit GlaxoSmithKline at www.gsk.com.
GSK in Oncology
GSK Oncology is dedicated to producing innovations in cancer that willmake profound differences in the lives of patients. Through GSK's "bench tobedside" approach, we are transforming the way treatments are discovered anddevelope
